Technical Analysis for ATX - Amplia Therapeutics Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.090 | 0.00% | 0.000 |
ATX closed unchanged on Thursday, November 21, 2024, on 16 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 200 DMA | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
200 DMA Support | Bullish | -5.26% | |
Narrow Range Bar | Range Contraction | -5.26% | |
Earnings Movers | Other | -5.26% |
Alert | Time |
---|---|
Rose Above 200 DMA | about 6 hours ago |
200 DMA Resistance | about 10 hours ago |
Up 2% | about 10 hours ago |
Up 3% | about 10 hours ago |
Up 1% | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3). FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Pharmaceutical Disease Diseases Cancer Drugs Tumor Oncology Chemotherapy Tumors Chronic Disease Fibrosis Ovarian Cancer Chronic Diseases Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Pharmaceutical Disease Diseases Cancer Drugs Tumor Oncology Chemotherapy Tumors Chronic Disease Fibrosis Ovarian Cancer Chronic Diseases Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.18 |
52 Week Low | 0.055 |
Average Volume | 1,011,399 |
200-Day Moving Average | 0.093 |
50-Day Moving Average | 0.129 |
20-Day Moving Average | 0.109 |
10-Day Moving Average | 0.095 |
Average True Range | 0.008 |
RSI (14) | 32.43 |
ADX | 32.43 |
+DI | 15.099 |
-DI | 35.289 |
Chandelier Exit (Long, 3 ATRs) | 0.135 |
Chandelier Exit (Short, 3 ATRs) | 0.111 |
Upper Bollinger Bands | 0.150 |
Lower Bollinger Band | 0.068 |
Percent B (%b) | 0.27 |
BandWidth | 75.963 |
MACD Line | -0.012 |
MACD Signal Line | -0.011 |
MACD Histogram | -0.0009 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.095 | ||||
Resistance 3 (R3) | 0.095 | 0.094 | 0.094 | ||
Resistance 2 (R2) | 0.094 | 0.093 | 0.094 | 0.093 | |
Resistance 1 (R1) | 0.092 | 0.092 | 0.092 | 0.092 | 0.093 |
Pivot Point | 0.091 | 0.091 | 0.091 | 0.091 | 0.091 |
Support 1 (S1) | 0.089 | 0.090 | 0.089 | 0.089 | 0.087 |
Support 2 (S2) | 0.088 | 0.089 | 0.088 | 0.087 | |
Support 3 (S3) | 0.086 | 0.088 | 0.086 | ||
Support 4 (S4) | 0.086 |